Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Rx Divestment Remains ‘On Track’

As Business Buffeted By COVID And Albuterol Woes

Executive Summary

Perrigo says its deal to divest its Rx business remains “on track,” with the company shunting the prescription unit into “discontinued operations” in the first quarter as it trains its focus on the firm’s future growth engine of consumer self-care.

You may also be interested in...



Perrigo Trades Rx For HRA With €1.8bn Acquisition

Perrigo has announced a deal to acquire consumer healthcare company HRA Pharma for €1.8bn. The move comes after the firm shed the majority of its prescription pharmaceuticals interests in recent years and completes its transformation into a fully self-care focused company.

Generics Industry Fails To Match Last Year’s Growth In First Quarter

The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies. 

Perrigo Divests In Brazil And Mexico

Perrigo has revealed plans to divest its OTC businesses in Brazil and Mexico to private equity firm Advent International, citing insufficient scale and weak margins.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150920

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel